In this prospective, nested case–control study, we found no evidence that the risk of pancreatic cancer was influenced by prediagnostic plasma levels of IGF-I, IGF-II, or IGFBP-3. This evidence concerns the gene IGF1 and familial pancreatic carcinoma.